Intellia doses first patient in CRISPR/Cas9 clinical trial of NTLA-2001 for ATTR
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progressionCredit: Intellia Therapeutics CAMBRIDGE, Mass., Nov. 9, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that...